Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | CASP1 | P29466 | 3/20 | 0.48 |
| ▸ | CASP7 | P55210 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17781277 | 0.87 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10HPGDNPC1 | |
| SCHEMBL21961701 | 0.84 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10HPGDNPC1 | |
| SCHEMBL19680296 | 0.82 | KDM4E (0.55) | KDM4EALDH1A1HSD17B10HPGDNPC1 | |
| SCHEMBL25117818 | 0.81 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10HPGDNPC1 | |
| SCHEMBL28489390 | 0.81 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10HPGDNPC1 | |
| SCHEMBL25117830 | 0.80 | ALDH1A1 (0.62) | KDM4EALDH1A1HSD17B10HPGDNPC1 | |
| SCHEMBL20697060 | 0.80 | KDM4E (0.64) | KDM4EALDH1A1HSD17B10HPGDNPC1 | |
| SCHEMBL25177366 | 0.79 | SMN1; SMN2 (0.50) | KDM4EALDH1A1HSD17B10HPGDNPC1 | |
| SCHEMBL25177371 | 0.79 | KDM4E (0.54) | KDM4EALDH1A1HSD17B10HPGDNPC1 | |
| SCHEMBL23516462 | 0.79 | TP53 (0.37) | KDM4EALDH1A1HSD17B10HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110938-A | Compound as protein kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-08-28 | — | — | US | disclosed |
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-04-17 | — | — | US | disclosed |
| WO-2025054448-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-03-13 | — | — | WO | disclosed |
| CN-113773335-B | Compound serving as protein kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-117412970-A | Solid form of fluorine-containing macrocyclic structure compound, preparation method and application | 成都倍特药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-114073704-B | Use of fluorine-containing heterocyclic derivative with macrocyclic structure | 赛诺哈勃药业（成都）有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-113336774-B | Substituted chiral diaryl macrocyclic compounds as TRK inhibitors | 江南大学 | 2023-05-23 | — | — | CN | disclosed |
| US-20230044722-A1 | FLUORINE-CONTAINING HETEROCYCLIC DERIVATIVES WITH MACROCYCLIC STRUCTURE AND USE THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| WO-2022218276-A1 | SOLID FORM OF FLUORINE-CONTAINING MACROCYCLIC STRUCTURE COMPOUND, PREPARATION METHOD, AND APPLICATION | 成都倍特药业股份有限公司 | 2022-10-20 | — | — | WO | disclosed |
| CN-112110938-B | Compound as protein kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-113336774-A | Substituted chiral diaryl macrocycles as TRK inhibitors | 江南大学 | 2021-09-03 | — | — | CN | disclosed |
| WO-2021115401-A1 | FLUORINE-CONTAINING HETEROCYCLIC DERIVATIVES WITH MACROCYCLIC STRUCTURE AND USE THEREOF | 成都倍特药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115401-A1 | FLUORINE-CONTAINING HETEROCYCLIC DERIVATIVES WITH MACROCYCLIC STRUCTURE AND USE THEREOF | 成都倍特药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-20210087206-A1 | MACROCYCLIC KINASE INHIBITORS AND THEIR USE | TURNING POINT THERAPEUTICS INC (US) | 2021-03-25 | — | — | US | disclosed |
| WO-2020257189-A1 | MACROCYCLES FOR TREATING DISEASE | Turning Point Therapeutics, Inc. (US) | 2020-12-24 | — | — | WO | disclosed |
| CN-112110938-A | Compound as protein kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20200392160-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | TP THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10745416-B2 | Macrocyclic compounds for treating disease | Turning Point Therapeutics, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200190110-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | Turning Point Therapeutics, Inc. (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, CAMKK1, AP2A1 | KDM4E 3245/4885ALDH1A1 3638/4885HSD17B10 2313/4885 |
| US-20200392160-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | VHL, DLD, PC | KDM4E 3114/4885ALDH1A1 1658/4885HSD17B10 1019/4885 |
| US-20200190110-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | VHL, DLD, PC | KDM4E 3114/4885ALDH1A1 1658/4885HSD17B10 1019/4885 |
| US-20230044722-A1 | FLUORINE-CONTAINING HETEROCYCLIC DERIVATIVES WITH MACROCYCLIC STRUCTURE AND USE THEREOF | FRK, BRAF, ERBB3 | KDM4E 2301/4885ALDH1A1 4290/4885HSD17B10 3043/4885 |
| US-10745416-B2 | Macrocyclic compounds for treating disease | VHL, DLD, PC | KDM4E 3114/4885ALDH1A1 1658/4885HSD17B10 1019/4885 |
| US-20210087206-A1 | MACROCYCLIC KINASE INHIBITORS AND THEIR USE | MAP3K20, LCK, MAP3K1 | KDM4E 1234/4885ALDH1A1 4479/4885HSD17B10 3836/4885 |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, AP2A1, CSNK1A1 | KDM4E 2966/4885ALDH1A1 3210/4885HSD17B10 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.